These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16637918)

  • 21. Autoimmune disorders of the neuromuscular junction.
    Vincent A
    Neurol India; 2008; 56(3):305-13. PubMed ID: 18974557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Autoimmune myasthenia and Lambert-Eaton myasthenic syndrome. Physiopathologic concepts].
    Eymard B
    Ann Med Interne (Paris); 1989; 140(6):462-6. PubMed ID: 2696402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
    Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
    Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myasthenia gravis Lambert-Eaton overlap syndrome.
    Oh SJ
    Muscle Nerve; 2016 Jan; 53(1):20-6. PubMed ID: 26418033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myasthenia and related disorders of the neuromuscular junction.
    Spillane J; Beeson DJ; Kullmann DM
    J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):850-7. PubMed ID: 20547629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical aspects of neuromuscular transmission disorders.
    Evoli A
    Acta Neurol Scand Suppl; 2006; 183():8-11. PubMed ID: 16637919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis.
    O'carroll P; Bertorini TE; Jacob G; Mitchell CW; Graff J
    J Clin Neuromuscul Dis; 2009 Dec; 11(2):69-71. PubMed ID: 19955986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The auto-antigen repertoire in myasthenia gravis.
    Vrolix K; Fraussen J; Molenaar PC; Losen M; Somers V; Stinissen P; De Baets MH; Martínez-Martínez P
    Autoimmunity; 2010 Aug; 43(5-6):380-400. PubMed ID: 20380581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-mediated disorders of neuromuscular transmission.
    Vincent A
    Suppl Clin Neurophysiol; 2004; 57():147-58. PubMed ID: 16106615
    [No Abstract]   [Full Text] [Related]  

  • 32. Myasthenia gravis experimentally induced with muscle-specific kinase.
    Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
    Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoantibodies in different forms of myasthenia gravis and in the Lambert-Eaton syndrome.
    Vincent A
    Handb Clin Neurol; 2008; 91():213-27. PubMed ID: 18631844
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antibodies to acetylcholine receptor in patients with different clinical forms of myasthenia and Lambert-Eaton myasthenic syndrome].
    Sidnev DV; Karganov MIu; Shcherbakova NI; Alchinova IB; Sanadze AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(1):53-5. PubMed ID: 16457135
    [No Abstract]   [Full Text] [Related]  

  • 35. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myasthenic syndromes.
    Farrugia ME
    J R Coll Physicians Edinb; 2011 Mar; 41(1):43-7; quiz 48. PubMed ID: 21365067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular targets for autoimmune and genetic disorders of neuromuscular transmission.
    Vincent A; Beeson D; Lang B
    Eur J Biochem; 2000 Dec; 267(23):6717-28. PubMed ID: 11082182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.
    Lennon VA; Kryzer TJ; Griesmann GE; O'Suilleabhain PE; Windebank AJ; Woppmann A; Miljanich GP; Lambert EH
    N Engl J Med; 1995 Jun; 332(22):1467-74. PubMed ID: 7739683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Autoantibodies in myasthenia gravis].
    Motomura M; Narita Masuda T
    Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis.
    Ha JC; Richman DP
    Biochim Biophys Acta; 2015 Apr; 1852(4):651-7. PubMed ID: 25486268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.